Welcome to our dedicated page for Nephros news (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros stock.
Nephros Inc. (Nasdaq: NEPH) is a commercial-stage medical device and water technology company dedicated to enhancing water quality in both medical and commercial markets. Founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center, Nephros initially aimed to address the needs of chronic renal failure patients. Today, the company is known for its innovative liquid purification filters that capture contaminants as small as 5 nanometers, significantly reducing exposure to a variety of pathogens, including bacteria, viruses, fungi, parasites, and endotoxins.
The heart of Nephros's technology lies in its proprietary hollow fiber design, which balances three critical elements for optimal filter performance: filtration precision, flow rate, and filter lifespan. These filters are highly efficient, providing up to 12 months of service with minimal disruption in flow rate, making them ideal for both healthcare and commercial applications.
In the medical sector, Nephros offers advanced water filtration products and waterborne pathogen detection tools. These products are essential for maintaining high standards of water safety, particularly in healthcare settings where water quality can directly impact patient outcomes. The company's subsidiary is actively working on a second-generation hemodiafiltration system and other devices aimed at improving therapies for renal disease patients.
In the commercial market, Nephros manufactures water filters designed to enhance the taste and odor of water, while also reducing biofilm, bacteria, and scale buildup in downstream equipment. These products cater to a wide range of industries, including hospitality, food service, and manufacturing, where water quality is a critical factor.
Nephros has recently achieved significant milestones, including:
- Filing its third-quarter financial results on November 8, 2023, with a subsequent conference call to discuss the outcomes.
- Hosting investor relations calls to keep stakeholders informed about company developments.
- Continued commitment to providing cutting-edge water filtration solutions and education to improve water safety.
With a mission to improve the human relationship with water, Nephros remains at the forefront of water technology innovation, offering proactive and emergency solutions to ensure water quality across various sectors. For more information, visit the company's website at Nephros.com.
Nephros (Nasdaq: NEPH), a leading water technology company specializing in medical and commercial filtration solutions, has announced its participation in the Benchmark Company 13th Annual Discovery One-on-One Investor Conference. The event will take place on December 11, 2024, at the New York Athletic Club in New York City.
CEO Robert Banks and CFO Judy Krandel will represent Nephros at the conference, conducting one-on-one and group meetings with investors and analysts throughout the day. The conference format is designed to connect emerging growth companies with institutional and individual investors.
Nephros reported Q3 2024 financial results with net revenue of $3.5 million, marking an 8% increase over Q2 2024 but a 6% decrease from Q3 2023. The company achieved its first profitable quarter with net income of $0.2 million, compared to a net loss of $0.2 million in Q3 2023. Gross margins improved to 61% from 59% year-over-year. Adjusted EBITDA reached $295,000, up from $11,000 in the same period last year. Cash position stood at $2.5 million as of September 30, 2024, down from $4.3 million at the end of 2023.
Nephros (Nasdaq: NEPH), a water technology company specializing in filtration solutions for healthcare and commercial markets, announced it will release its third-quarter 2024 financial results on Thursday, November 7, 2024, after market close. The company will host a conference call at 4:30pm ET the same day. Participants can join via domestic access (1-844-808-7106) or international access (1-412-317-5285). An audio archive will be available on the Nephros Investor Relations page, with replay access until November 14, 2024.
Nephros (Nasdaq: NEPH) has launched the HydraGuard 20" UltraFilter, expanding its filtration technology portfolio. The new filter offers higher-volume capacity and flow rate while removing bacteria, viruses, and endotoxins. This product enables Nephros to enter new markets, particularly medical device manufacturing and pharmaceutical production, supporting compliance with water quality standards like ANSI/AAMI ST108.
The filter builds upon existing HydraGuard technology, previously to dialysis water purification, and provides exceptional retention of microbiological contaminants through size exclusion, offering more reliable performance compared to charged membranes.
Nephros, Inc. (Nasdaq: NEPH), a leader in advanced filtration technology, has responded rapidly to the recent hurricanes Helene and Milton that devastated parts of the southeastern United States. The company provided important water filtration solutions to multiple healthcare and nursing care facilities affected by the storms, ensuring a safe water supply for patients and staff during recovery efforts.
Nephros has shipped a significant number of filters, responding after hours and delivering next day to both federal and local disaster response partners. Their solutions have been deployed across multiple states and facility types, including:
- Florida hospitals where Nephros in-line filters were previously installed
- North Carolina nursing and care facilities where point-of-use filters provided immediate protection against bacteria
The company's ability to act quickly in disaster response situations underscores its commitment to clean water access, offering an effective alternative to typical emergency water sources.
Nephros (NEPH) reported Q2 2024 financial results with net revenue of $3.3 million, an 8% decrease from Q2 2023. However, programmatic revenue increased by 8% year-over-year, driven by over 300 new accounts added in the past 12 months. The company reported a net loss of $0.3 million, an improvement from $0.4 million in Q2 2023. Adjusted EBITDA was ($133,000), compared to ($183,000) in the prior year.
CEO Robert Banks highlighted growth in the core programmatic business but noted a decline in emergency response sales. The company is developing new business models to address challenges in filter changeout schedules. As of June 30, 2024, Nephros had cash and cash equivalents of $3.1 million.
Nephros Inc (Nasdaq: NEPH), a leading water technology company, has announced its schedule for the second quarter 2024 financial results conference call. The company will file its Q2 financial results on Thursday, August 8, 2024 after market close and host a conference call at 4:30pm ET the same day. Participants can join the call using the following dial-in numbers:
- Domestic access: 1 (844) 808-7106
- International access: 1 (412) 317-5285
An audio archive will be available on the Nephros Investor Relations page shortly after the call. A replay will also be accessible until August 15, 2024, using specific replay access codes for domestic and international callers.
FAQ
What is the current stock price of Nephros (NEPH)?
What is the market cap of Nephros (NEPH)?
What does Nephros Inc. specialize in?
When was Nephros Inc. founded?
What is the core technology of Nephros filters?
What markets does Nephros serve?
What recent achievements has Nephros announced?
How long do Nephros filters last?
How does Nephros contribute to water safety in medical settings?
What is mid-dilution hemodiafiltration (mid-HDF)?
Who are the key contacts for investor relations at Nephros?
Where can I find more information about Nephros?
